You are currently viewing the editor's summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Controlling amyloid in brain and vasculature
The genetic variant ε4 of the gene APOE (APOE4) is associated with increased risk of developing Alzheimer’s disease (AD). In AD, Aβ forms deposits in the brain parenchyma (amyloid plaques) and in the cerebral vasculature [cerebral amyloid angiopathy (CAA)]. Immunotherapy targeting human APOE reduced brain Aβ deposits in mice. Now, Xiong et al. used a mouse model with both amyloid plaques and CAA and evaluated the effects of the anti-human APOE antibody HAE-4. The treatment reduced both parenchymal Aβ plaques and CAA without vascular complications, whereas an antibody targeting Aβ exacerbated CAA-related microhemorrhages. The results suggest that HAE-4 may provide therapeutic effects on amyloid removal in AD while protecting the cerebrovasculature.
- Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
This is an article distributed under the terms of the Science Journals Default License.
